KIT and melanoma: Partial responses to KIT inhibitors have been observed in less than 20% of patients with acral, mucosal and chronically sun-damaged melanoma patients, reporting a median overall survival of 46 weeks with imatinib and 7.5 months with dasatinib [74,75].